Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Esperion Therapeutics top riser on Nasdaq as FDA impressed

Monday, March 20, 2017 8:41
% of readers think this story is Fact. Add your two cents.

Esperion Therapeutics Inc (NASDAQ:ESPN) was top riser on Nasdaq Monday, with shares up over 48% as it received welcome feedback from the powerful US FDA on its cholesterol-lowering drug candidate.

The regulatory body said the firm’s late-stage clinical program would be enough to support approval for the candidate.

The drug is aimed specifically as a supplementary treatment to statin therapy in patients with high cardiovascular disease risk.

Esperion plans to apply for FDA approval by the first half of 2019, with results from a phase 3 trial expected by the second quarter of 2018.

Tim Mayleben, chief executive of the biotech, said: “We are very pleased to have achieved clarity from FDA regarding Esperion’s LDL-C lowering development program.

“Our experienced lipid management team has worked closely with regulatory authorities and our key advisors to achieve this encouraging outcome.

“We continue to believe that bempedoic acid has the potential to provide physicians with a complementary and convenient oral treatment option that’s cost-effective for their patients with hypercholesterolemia who require additional LDL-C lowering.

“We remain focused on completing the global pivotal Phase 3 program for bempedoic acid and reporting top-line results from our long-term safety and tolerability study by Q2 2018 and top-line results from our ongoing Phase 3 LDL-C lowering efficacy studies by mid-2018.”

Shares gained 48.2% to stand at $34.58 a pop.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.